Government Increases Oversight for Non-Accredited Educational Activities
Canadian Pharma Must Be Ready
How to Prepare for Key Regulatory Hurdles in Canada
A New IQVIA Commercial Compliance White Paper
In a climate of increased scrutiny from regulatory bodies, the Canadian pharmaceutical industry should prepare for changes, perhaps significant; regarding the class of activities called Non-Accredited Educational Activities—also referred to as Other Learning Activities (OLAs).
Health Canada, advertising preclearance agencies including the Pharmaceutical Advertising Advisory Board, Advertising Standards Canada and MIJO (formerly the Broadcast Clearance Advisory), as well as medical associations such as Innovative Medicines Canada, have all recently enhanced or clarified what is permitted and what is prohibited pertaining to pharmaceutical companies' development and execution of OLAs. These updates follow Health Canada's December 2018 launch of proactive monitoring of health products advertising.
Download this new IQVIA Commercial Compliance white paper, and discover:
- How to prepare for these regulatory hurdles in Canada
- The importance of comprehensive reporting
- Key ways to implement compliance and risk mitigation strategies around OLAs
- How IQVIA's industry leading solutions can help Life Sciences companies prepare for the expansion and enforcement of regulatory guidance
- And more
For more information about IQVIA Commercial Compliance, please e-mail email@example.com or visit our webpage. Our experts leverage the industry's leading technologies to deliver streamlined processes and improved efficiencies that solve your toughest engagement and transparency challenges. From automating and managing the entire HCP/O contracting lifecycle, to capturing, collecting, and reporting global spend; to planning efficient and compliant HCP meetings and engagements—discover how our solutions can make compliance easier for you.